Zobrazeno 1 - 10
of 13
pro vyhledávání: '"35"'
Publikováno v:
Blood. 110:3526-3531
Patients with severe immune thrombocytopenic purpura (ITP) may require an acute increase in the platelet count for surgery or ongoing hemorrhage as well as long-term maintenance treatment. Certain of these patients may be refractory to steroids, intr
Autor:
Mohammad Azab, Amy E. DeZern, James K. McCloskey, David P. Steensma, Michael R. Savona, Lambert Busque, Richard A. Wells, Hagop M. Kantarjian, Laura C. Michaelis, Elizabeth A. Griffiths, Casey O'Connell, Gail J. Roboz, Olatoyosi Odenike, Joseph M. Brandwein, Guillermo Garcia-Manero, Aram Oganesian, Karen W.L. Yee
Publikováno v:
Blood
This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20 mg/m2 IV. Adults with International Prognostic Scori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec61fb49d6a9972c3dc4da643b0d31e
https://europepmc.org/articles/PMC7414597/
https://europepmc.org/articles/PMC7414597/
Autor:
Timothy M Illidge, Andrew Davies, Steven M. Horwitz, Barbara Pro, Dana A. Kennedy, Andres Forero-Torres, Ranjana H. Advani, Michelle A. Fanale, Hong Ren, Shih Yuan Lee, Andrei R. Shustov, Robert W. Chen, Mayur Uttarwar, Nancy L. Bartlett
Publikováno v:
Blood. 131:2120-2124
This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD30+ peripheral T-cell lymph
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Meletios A. Dimopoulos, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Pierre Morel, Giovanni Palladini, Xavier Leleu, Alessandra Tedeschi, Ramón García-Sanz, Efstathios Kastritis, Eurydiki Michalis, Zafiris Kartasis, Giampaolo Merlini, Dimitra Gika, Pieter Sonneveld
Publikováno v:
Blood, 122(19), 3276-3282. American Society of Hematology
In this phase 2 multicenter trial, we evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) combination in previously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM). To prevent immunoglobulin M (IgM) "flare,
Autor:
Richard J. Q. McNally, Tryfonia Mainou-Fowler, Peter W. James, H Lucraft, Gail Jones, Gillian Watson, Katrina M Wood, Michael J Galloway, John R. Goodlad, Jennifer Wilkinson, Dominic Culligan, Stephen J. Proctor
Publikováno v:
Blood. 119:6005-6015
The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median a
Autor:
Simon Lyons, Peter Forsyth, John Davies, Kathryn Boyd, Philip Mounter, Nithia Angamuthu, Anne Lennard, Stephen J. Proctor, Richard Chasty, Paul Revell, Fergus Jack, Michal Sieniawski
Publikováno v:
Blood. 115:3664-3670
Enteropathy associated T-cell lymphoma (EATL) is a rare type of peripheral T-cell lymphoma. At present, there are no standardized diagnostic or treatment protocols for EATL. We describe EATL in a population-based setting and evaluate a new treatment
Autor:
Susan O'Brien, Michael J. Keating, Constantine S. Tam, William G. Wierda, Alice Lynn, Neil E. Kay, Daniel L. Van Dyke, Alessandra Ferrajoli, Tait D. Shanafelt, Lynne V. Abruzzo, Susan Lerner
Publikováno v:
Blood. 114:957-964
To determine the clinical fate of patients with de novo deletion 17p13.1 (17p−) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p− CLL patients from the M. D. Anderson Cancer Center (n = 64) and
Autor:
John Radford, R. Capizzi, Julie M. Vose, John M. Bennett, Mark S. Kaminski, John P. Leonard, Andrew D. Zelenetz, Stewart Kroll, Sandra J. Horning, Oliver W. Press, Susan J. Knox
Publikováno v:
Blood. 105:4576-4582
The incidence of treatment-related myelodysplastic syndromes and acute myeloid leukemia (tMDSs/tAML) after tositumomab and iodine I(131) tositumomab administration to previously treated and untreated patients with non-Hodgkin lymphoma (NHL) was evalu
Autor:
Tony Williams, Sergio Santillana, Elihu H. Estey, Dan Douer, John M. Bennett, Gabriel Lopez-Bernstein, Kristi A. Boehm
Publikováno v:
Blood. 97:73-80
A novel intravenous liposomal formulation of all-transretinoic acid (ATRA) was evaluated in 69 patients with acute promyelocytic leukemia (APL): 32 new diagnoses, 35 relapses, and 2 oral ATRA failures. Liposomal ATRA (90 mg/m2) was administered every